0000899243-20-027232.txt : 20201005 0000899243-20-027232.hdr.sgml : 20201005 20201005160533 ACCESSION NUMBER: 0000899243-20-027232 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201001 FILED AS OF DATE: 20201005 DATE AS OF CHANGE: 20201005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS CENTRAL INDEX KEY: 0001779990 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 201223566 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-01 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001779990 HENDERSON MICHAEL THOMAS C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 Chief Business Officer Common Stock 2020-10-01 4 M 0 3255 0.28 A 271006 D Common Stock 2020-10-01 4 M 0 6745 1.05 A 277751 D Common Stock 2020-10-01 4 S 0 4495 38.2855 D 273256 D Common Stock 2020-10-01 4 S 0 5505 39.2822 D 267751 D Stock Option (Right to Buy) 0.28 2020-10-01 4 M 0 2236 0.00 D 2020-05-19 2027-11-13 Common Stock 2236 0 D Stock Option (Right to Buy) 0.28 2020-10-01 4 M 0 1019 0.00 D 2020-05-19 2028-05-07 Common Stock 1019 0 D Stock Option (Right to Buy) 1.05 2020-10-01 4 M 0 6745 0.00 D 2020-05-19 2029-09-24 Common Stock 6745 38282 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Represents the weighted average sale price of the shares sold from $37.74 to $38.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Represents the weighted average sale price of the shares sold from $38.81 to $39.71 per share. /s/ Tara Condon, Attorney-in-Fact 2020-10-04